Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Phase 2
Terminated
NCT05971602
| Condition | Pulmonary Tuberculosis |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Gates Medical Research Institute |
|---|
| Status | Terminated |
|---|
| Enrollment | 93 participants |
|---|
| Interventions | Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS), Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS), Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE), Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS), Isoniazid and Rifampicin (HR) |
|---|
| Start date | Jul 26, 2023 |
|---|
| Completion date | Feb 6, 2025 |
|---|
| Results posted | May 20, 2026 |
|---|
Summary
This multicenter, two-stage, open-label, randomized trial will aim to assess the efficacy, safety, optimal duration, and pharmacokinetics (PK) of Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS) and Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS) in adult participants with drug sensitive tuberculosis (DS-TB) and rifampicin or multi-drug resistant TB (RR/MDR-TB).
Percentage of Participants With DS-TB Reporting ≥ Grade 3 Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
Two weeks after the end of treatment [19 weeks for Arm 1 (DBOS) and Arm 2 (PBOS), and 28 weeks for Arm 3 (HRZE)] · percentage of participants
| Arm 1: Delamanid + Bedaquiline + OPC-167832 + Sutezolid (DBOS) | 16.7 percentage of participants |
|---|
| Arm 2: Pretomanid + Bedaquiline + OPC-167832 + Sutezolid (PBOS) | 6.3 percentage of participants |
|---|
| Arm 1: Delamanid + Bedaquiline + OPC-167832 + Sutezolid (DBOS) | 10 percentage of participants |
|---|
| Arm 2: Pretomanid + Bedaquiline + OPC-167832 + Sutezolid (PBOS) | 3.1 percentage of participants |
|---|
| Arm 3: HRZE-Regimen | 6.5 percentage of participants |
|---|
| Arm 3: HRZE-Regimen | 6.5 percentage of participants |
|---|
Percentage of Participants With Pulmonary DS-TB With Unfavorable Outcome Status
Through Week 17 post-randomization for Arm 1 (DBOS) and Arm 2 (PBOS), and Week 26 post-randomization for Arm 3 (HRZE) · Percentage of participants
| Arm 1: Delamanid + Bedaquiline + OPC-167832 + Sutezolid (DBOS) | 9.1 Percentage of participants |
|---|
| Arm 2: Pretomanid + Bedaquiline + OPC-167832 + Sutezolid (PBOS) | 0 Percentage of participants |
|---|
| Arm 3: HRZE-Regimen | 18.8 Percentage of participants |
|---|
| Unstratified treatment differences | -9.7 (95% CI -37.0–13.9) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.